Skip to content

Qingke Pingchuan granules for adult community-acquired pneumonia with syndrome of phlegm heat obstructing lung: a randomized, double-blind, placebo-controlled trial

Qingke Pingchuan granules for adult community-acquired pneumonia with syndrome of phlegm heat obstructing lung: a randomized, double-blind, placebo-controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043207
Enrollment
Unknown
Registered
2021-02-08
Start date
2021-02-08
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-Acquired Pneumonia

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are aged 18–65 years; 2. Patients who meet the diagnostic criteria of CAP; 3. Patients who meet the Chinese medicine syndrome classification of phlegm heat obstructing lung; 4. CURB-65 score is 0-2 points; 5. Patients who sign the written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe pneumonia; 2. Other respiratory diseases: bronchial asthma, bronchiectasis, bullae, pleural effusion, active tuberculosis and other lung diseases; 3. Severe or uncontrollable basic diseases:hematological diseases; liver dysfunction (ALT or AST >= 3ULN, total bilirubin >= 1.5ULN), renal dysfunction (serum creatinine > 177µmol/L or 2mg/dl), congestive heart failure (III-IV); immune deficiency, tumor, organ or bone marrow transplantation, HIV or immunosuppressive therapy in recent 3 months; 4. Patients with diabetes or impaired glucose tolerance; 5. Patients with confirmed history of alcohol, drug abuse or mental illness; 6. Patients with dysphagia or gastrointestinal disease affecting drug absorption (reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, after subtotal gastrectomy); 7. Patients who have known hypersensitivity to the study medication or some of its ingredients; 8. Patines have been exposed to the study drug within one month before enrollment; 9. Patients who are pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Modified imaging absorption assessment scale for pneumonia;

Secondary

MeasureTime frame
Cough symptom score;The proportion and time of cough disappearance;The proportion and time of phlegm disappearance;CASA-Q;CURB-65;WBC;CRP;PCT;Classification of sputum cytology;Average treatment days;

Countries

China

Contacts

Public ContactLin Lin

Guangdong Provincial Hospital of Chinese Medicine

drlinlin620@163.com+86 20 80887233 38605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026